Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]JMJ-129-d2
- Development stage
- Phase 1
- Lead developer
- National Institute of Mental Health
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
`[11C]JMJ-129-d2` is a carbon-11 labeled, deuterated small molecule positron emission tomography (PET) radioligand developed by the National Institute of Mental Health (NIMH) for imaging and quantifying phosphodiesterase-4D (PDE4D) in the brain. PDE4D is an enzyme that hydrolyzes cyclic adenosine monophosphate (cAMP) and is implicated in cognitive function, depression, and neurodegenerative diseases such as Alzheimer's disease. `[11C]JMJ-129-d2` was designed as a deuterated analogue of `[11C]JMJ-129` to overcome the issue of brain-penetrant, lipophilic radiometabolites that interfered with the quantification of PDE4D in human brain imaging. By incorporating deuterium, the rate of oxidative hydroxylation is slowed, reducing the formation of these troublesome radiometabolites and improving the accuracy of PET imaging. The radioligand is currently in Phase 1 clinical development for brain imaging in healthy volunteers.
- Other names
- [¹¹C]JMJ-129-d2carbon-11 JMJ-129-d2carbon11 JMJ-129-d2carbon 11 JMJ-129-d2
02
Targets
PDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)PDE4D (Phosphodiesterase 4D)
Beyond the preview
Go deeper on [11C]JMJ-129-d2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [11C]JMJ-129-d2.